89bio Corp (ETNB): Price to Sales

Corporate company logo of 89bio Corp (ETNB)

89bio, Inc. (ETNB) is developing innovative MASH/NASH therapies, leveraging the success of pegozafermin and the potential for acquisition by industry behemoths. The price-to-sales valuation on this chart helps identify if the asset is overbought, while the value of reflects the most recent figure. The digitalization of screenings is accelerating the discovery of formulas, yet a heavy reliance on a single molecule creates significant binary risks.

89bio - ETNB P/S Multiple (period 07/04/2022 - 11/13/2026)

Metric breakdowns and analytics for 89bio Corp (ETNB)

- current price and projected stock value:
Price Chart 89bio.com|ETNB - Price Target Chart
- stock exchange capitalization data:
Market Value 89bio Corp|ETNB - Total Company Value
- shareholders' equity book value data:
Net Assets per Single Share 89bio|ETNB - Book Capitalization|Market Capitalization to Book Value 89bio.com|ETNB - Aggregate Company Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Coefficient 89bio, Inc.|ETNB - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio 89bio Pharma|ETNB - Aggregate Debt Obligations|Debts to Net Assets 89bio Corp|ETNB - Company Long-Term Debts|Company Short-Term Debt 89bio|Interim Coverage Ratio 89bio.com
- financial results and valuation multiples details:
ETNB - Company Net Income|Expected Net Profit 89bio, Inc.|ETNB - Price to Earnings Ratio|Future Price to Earnings Multiple 89bio Inc|ETNB - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio 89bio Corp|ETNB - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months 89bio|ETNB - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months 89bio.com|ETNB - Net earnings per share growth this year|Consensus forecast of earnings per share growth for next year 89bio, Inc.
- issuer revenue and sales details:
ETNB - Revenue and Sales Volume|Company Expected Sales Volume 89bio.com|ETNB - Market Cap to Revenue|Price to Expected Revenue Ratio 89bio Corp
Basic company analysis:ETNB, 89bio.com
Core merchandise of 89bio, Inc.

For the biotech developer 89bio, Inc. (ETNB), which possesses the potential to create low-cost blockbuster drugs, the P/S ratio reflects market expectations for future sales scalability. This metric correlates current market capitalization with revenue, allowing the calculated P/S to determine the degree of asset overvaluation relative to actual operating flows and accurately capture the phases of the company's cyclical valuation changes.

Competing companies

Price-to-Revenue Ratio ASND (ascendispharma.com)|Price-to-Revenue Ratio Madrigal Pharmaceuticals, Inc. MDGL|Corcept Therapeutics Inc. (CORT) - Price to Sales|RYTM - Price-to-Revenue Ratio|AKRO: Price-to-Revenue Ratio|MTSR: P/S Multiple|MLTX - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Crinetics|NewAmsterdam Pharma Company (NAMS) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Soleno (SLNO)|Market Cap to Revenue Amicus Corp FOLD|Market Capitalization-to-Revenue Ratio Agios Pharmaceuticals|Price-to-Revenue Coefficient structuretx.com (GPCR)|MiMedx - P/S Multiple|RZLT: Price-to-Revenue Ratio|LXRX: P/S Multiple|MBX - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Altimmune, Inc.|Price to Sales aardvarktherapeutics.com AARD|Market Cap to Revenue SGMT (Sagimet Biosciences Inc.)|BIOA (BioAge Labs) - Market Capitalization-to-Revenue Ratio|P/S Multiple BMEA (Biomea)|Price-to-Revenue Coefficient Quince Therapeutics Inc (QNCX)|GUTS - Price-to-Revenue Ratio|VTVT (vTv Therapeutics Inc.) - Market Cap to Revenue Ratio|ATPC: P/S Multiple|Market Cap to Revenue Pluri|Market Cap to Revenue SYBX|Lipocine Corporation (LPCN) - Price-to-Revenue Coefficient|P/S Multiple MTNB|SPRB - Price to Sales|Galecto - Market Cap to Revenue|Market Cap to Sales Volume CTCX (Carmell Corp.)|LUMO - Price-to-Revenue Ratio|ONVO (Organovo Corp) - Market Cap to Revenue Ratio|RDUS: P/S Multiple